Septicemia or Severe Sepsis with MV >96 Hours DRG Reimbursement

Summary & Overview

Septicemia or Severe Sepsis with MV >96 Hours: Inpatient Reimbursement Overview

DRG 870 encompasses septicemia or severe sepsis requiring invasive mechanical ventilation for more than 96 hours, reflecting severe systemic infection with prolonged respiratory failure. It matters for inpatient reimbursement because it represents one of the highest-acuity Diagnosis-Related Groups with substantially greater resource intensity and payment under Medicare rules.

SepticemiaDRG Septicemia or Severe Sepsis with MV >96 HoursDRG 870Diagnosis-Related GroupInpatient ReimbursementMedicareIntensive CareMechanical VentilationCritical CareInfectious Disease

DRG 870 Overview

DRG 870 covers inpatient hospitalizations for patients with septicemia or severe sepsis who require invasive mechanical ventilation for more than 96 hours, representing high-acuity critical care. This Diagnosis-Related Group captures complex cases with prolonged respiratory support and multiple organ dysfunction that drive resource use. As a high-weight Diagnosis-Related Group, it is a primary driver of higher Medicare reimbursement for intensive care stay and advanced life-sustaining therapies. Accurate diagnosis and procedure documentation directly affect case classification and payment under Centers for Medicare & Medicaid Services rules.

National Payment Rates

Across commercial payers the observed rate range spans from about $53K to $140K among the provided payer benchmarks, with maximums reported up to $230K. The widest spread between payer means and maximums is most pronounced for Anthem and Cigna in the table and chart below. Refer to the table and chart for payer-specific percentiles and distribution details.

Mean Rates by Payer — National — DRG 870

The CMS 2023 data are national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 870. These figures reflect national Medicare payment and charge measures for the recorded discharges.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

For DRG 870 in Alaska the payer rate range spans from $110K to $170K among the reported payers, with BCBS and Anthem clustered at $110K and Cigna markedly higher with a mean of $170K and a max of $280K. This produces a notable deviation above several national medians, driven primarily by Cigna’s elevated values. See the table and chart below for the full payer distribution.

Key Insights for Alaska

Blue Cross Blue Shield (BCBS) and Anthem both report a single benchmark value of $110K, tying as the lowest-paying payers in Alaska for DRG 870.
Cigna is the highest-paying payer with a mean of $170K and an upper range up to $280K, creating a wide state payer spread and concentration above national medians.
Alaska’s payer means skew higher than many national benchmarks — notably Cigna’s $170K mean exceeds typical national medians for this DRG, indicating a meaningful upward deviation from national rates.

Clinical Trials

Acute critical care intervention trials assessing ventilation strategies, adjunctive hemodynamic support, or early sepsis bundle components in patients with septicemia or severe sepsis requiring mechanical ventilation >96 hours. These studies enroll critically ill adult ICU patients shortly after diagnosis of sepsis and intubation to evaluate interventions aimed at reducing time on the ventilator, organ dysfunction progression, or ICU mortality; they focus on immediate-phase management choices such as lung-protective ventilation settings, fluid-resuscitation protocols, or vasopressor titration strategies. Results are highly relevant to providers and payers because improved early management can shorten ICU length of stay, reduce resource-intensive ventilator days, and lower costs associated with prolonged mechanical ventilation and organ support.
Comparative effectiveness and stewardship studies examining antimicrobial regimens, de-escalation timing, or diagnostic stewardship in patients with culture-positive or culture-negative septicemia who remain ventilator-dependent beyond 96 hours. These trials compare antibiotic selection strategies, duration of therapy, and rapid diagnostic-guided approaches in a population at high risk for secondary infections, multidrug-resistant pathogens, and antibiotic-related complications. Findings inform clinicians and payers about optimal antibiotic use that balances clinical outcomes with antimicrobial resistance risk and medication costs, potentially reducing readmissions and downstream expenditures related to complications.
Post-discharge outcomes and recovery studies evaluating long-term functional status, cognitive impairment, rehospitalization, and cost-effectiveness of post-ICU rehabilitation programs for survivors of severe sepsis who required >96 hours of mechanical ventilation. These cohort studies or randomized pragmatic trials follow patients after hospital discharge to measure physical functioning, quality of life, caregiver burden, and healthcare utilization, testing interventions such as structured physical therapy, outpatient critical care follow-up, or transitional care models. This research is relevant because patients in this DRG frequently experience prolonged disability and high post-discharge costs; evidence on effective recovery pathways helps payers and health systems plan resource allocation and value-based care strategies.

Related Codes

866-VIRAL-ILLNESS-WITHOUT-MCC

Viral Illness without MCC: Inpatient Reimbursement Overview

869-OTHER-INFECTIOUS-AND-PARASITIC-DISEASES-DIAGNOSES-WITHOUT-CC-MCC

Other Infectious and Parasitic Diseases Diagnoses without CC/MCC: Inpatient Reimbursement Overview

864-FEVER-AND-INFLAMMATORY-CONDITIONS

Fever and Inflammatory Conditions: Inpatient Reimbursement Overview

865-VIRAL-ILLNESS-WITH-MCC

Viral Illness with MCC: Inpatient Reimbursement Overview

855-INFECTIOUS-AND-PARASITIC-DISEASES-WITH-O-R-PROCEDURES-WITHOUT-CC-MCC

Infectious and Parasitic Diseases with O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

871-SEPTICEMIA-OR-SEVERE-SEPSIS-WITHOUT-MV-96-HOURS-WITH-MCC

Septicemia or Severe Sepsis without MV >96 Hours with MCC: Inpatient Reimbursement Overview

862-POSTOPERATIVE-AND-POST-TRAUMATIC-INFECTIONS-WITH-MCC

Postoperative and Post-Traumatic Infections with MCC: Inpatient Reimbursement Overview

858-POSTOPERATIVE-OR-POST-TRAUMATIC-INFECTIONS-WITH-O-R-PROCEDURES-WITHOUT-CC-MCC

Postoperative or Post-Traumatic Infections with O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

872-SEPTICEMIA-OR-SEVERE-SEPSIS-WITHOUT-MV-96-HOURS-WITHOUT-MCC

Septicemia or Severe Sepsis without MV >96 Hours without MCC: Inpatient Reimbursement Overview

863-POSTOPERATIVE-AND-POST-TRAUMATIC-INFECTIONS-WITHOUT-MCC

Postoperative and Post-Traumatic Infections without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 16

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Septicemia or Severe Sepsis with MV >96 Hours: Inpatient Reimbursement Overview

DRG 870 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes